Scientists have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherpy CAR-T cells in patients with B cell lymphomas. Individualized microbiome information retreaved from patients' gut microbiomes prior to initiation of CAR T therapy could accurately predict their subsequent responsiveness to therapy, but only in the condition that these patients were not pre-treated with broad spectrum antibiotics.
